An Epidemiologic Characterization of the TMPRSS2: ERG Subtype of Prostate Cancer
Lecture | February 6 | 2:30-3:30 p.m. | 150 University Hall
Nearly half of prostate tumors harbor the somatic TMPRSS2:ERG gene fusion, annually yielding diagnoses of more than 100,000 fusion-positive prostate cancers in the United States. Such cancers represent a unique paradigm of malignancy one in which an oncogene (ERG) becomes regulated by androgens because it is fused to a gene that is androgen-regulated (TMPRSS2). The etiology and disease courses of prostate cancers exhibiting TMPRSS2:ERG are thus likely to be unique. Over the past eight years, much of my research has focused on elucidating the importance of the TMPRSS2:ERG molecular subtype of prostate cancer. In discussing the epidemiology of this subtype, I will speak to lifestyle, biomarkers, clinical relevance, and genetics.